Insilico Medicine and Servier have advanced an AI-driven oncology collaboration into an early drug discovery milestone for the first program, triggered by target nomination and predefined criteria being met.

Under the deal, Insilico leads AI-driven discovery and early development, while Servier shares R&D costs and will handle clinical validation and commercialization.

Two oncology programs were launched in 2026, with target nominations completed for both, and the first program hitting the early drug discovery milestone, triggering an undisclosed milestone payment to Insilico.

Insilico reported strong first-half 2026 results with about $106 million in revenue (up roughly 287% year over year) and an adjusted net profit above $51 million, amid disclosed deal value for signed collaborations in 2026 totaling about $7.3 billion and approaching $11 billion cumulatively since 2021.

The broader 2026 activity includes numerous collaborations, with disclosed deal value for signed agreements in 2026 around $7.3 billion, lifting cumulative signed deal value since 2021 toward $11 billion.

In H1 2026, Insilico achieved its first profitable half-year since listing, reporting approximately $106 million in revenue and an adjusted net profit over $51 million.

The interim 2026 report notes 11 preclinical candidate nominations in the first ten months of 2026, bringing total PCC nominations since 2021 to 35, and eight clinical milestones across internal and partnered pipelines, led by Rentosertib (ISM001-055) which has entered Phase III for IPF.

In the first ten months of 2026, Insilico identified 11 developmental candidates for internal pipelines, contributing to a record 35 preclinical candidate nominations since 2021.

Rentosertib (ISM001-055) leads internal and partnered R&D advances, having entered Phase III for idiopathic pulmonary fibrosis.

Alex Zhavoronkov, PhD, founder, CEO and CBO of Insilico, emphasized the efficiency and quality AI brings to drug discovery, noting 11 internal developmental candidates identified in the first ten months of 2026.

The collaboration is valued at up to $888 million, with $32 million in upfront and near-term R&D payments identified in the agreement.

The milestone underscores the efficacy of Insilico's Pharma.AI platform in deciphering complex biology and rapidly generating high-quality compounds, accelerating early-stage research timelines.